

ASX Announcement

Board Change

Melbourne, Australia 2 January 2020: Prescient Therapeutics Limited (ASX: PTX) (“Prescient”), a clinical stage company developing personalised medicine approaches to cancer, announced that Mr Paul Hopper will today step down from his role as Non-executive Director in order to pursue other business interests.

Mr Hopper was a founding Director of Prescient in 2014.

Prescient Chairman, Mr Steve Engle, said “We thank Paul for his tremendous contributions to the Company, first as an Executive Director and in recent years as a Non-executive Director. We wish him all the best in his future endeavours.”

Mr Hopper said, “It has been an honour to serve on the Board of the Company. I look forward to tracking the progress of Prescient throughout 2020 and beyond.”

-Ends-

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumors, PTX-100 was well tolerated and achieved stable disease.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in recurrent or persistent platinum resistant ovarian cancer:

Cell Therapy: Prescient has a collaboration with Carina Biotech developing new CAR-T therapy approaches.

Find out more at ptxtherapeutics.com, or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/prescient-therapeutics).

The Board of Prescient Therapeutics Limited have approved the release of this announcement.

For more information please contact:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440

Andrew Geddes
CityPR
+61 2 9267 4511